The STATs of cancer — new molecular targets come of age
暂无分享,去创建一个
[1] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[2] Georg Breier,et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.
[3] R. Weinberg,et al. The pathway to signal achievement , 1993, Nature.
[4] D. Levy,et al. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. , 1993, Science.
[5] K. Kinzler,et al. The multistep nature of cancer. , 1993, Trends in genetics : TIG.
[6] A. Ullrich,et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.
[7] J. Darnell,et al. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.
[8] J. Darnell,et al. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. , 1994, The Journal of biological chemistry.
[9] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[10] R. Jove,et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.
[11] D. Carbone,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.
[12] B. Ponder,et al. Molecular Genetics of Cancer , 1992, Nature Medicine.
[13] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[14] J. Darnell,et al. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Darnell. STATs and gene regulation. , 1997, Science.
[16] T. Kishimoto,et al. Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.
[17] J. Parsons,et al. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. , 1997, Current opinion in cell biology.
[18] L. Hennighausen,et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. , 1997, Genes & development.
[19] S. Akira,et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Jove,et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[21] M. McMahon,et al. Identification and Characterization of a Constitutively Active STAT5 Mutant That Promotes Cell Proliferation , 2022 .
[22] Michael P. Brown,et al. Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses , 1998, Cell.
[23] J. Turkson,et al. Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.
[24] J. Darnell. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[25] G. Stark,et al. How cells respond to interferons. , 1998, Annual review of biochemistry.
[26] J. Darnell,et al. Stat3 Activation Is Required for Cellular Transformation by v-src , 1998, Molecular and Cellular Biology.
[27] J. Grandis,et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.
[28] R. Jove,et al. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. , 1999, Current opinion in oncology.
[29] Chi V. Dang,et al. c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.
[30] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[31] G. Prendergast,et al. Mechanisms of apoptosis by c-Myc , 1999, Oncogene.
[32] H. Lodish,et al. Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice A Direct Role for Stat5 in Bcl-XL Induction , 1999, Cell.
[33] T. Veikkola,et al. VEGFs, receptors and angiogenesis. , 1999, Seminars in cancer biology.
[34] S. Akira,et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.
[35] Protein tyrosine kinase inhibitors as novel therapeutic agents. , 1999, Pharmacology & therapeutics.
[36] J. Turkson,et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.
[37] M. Jaroszeski,et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.
[38] T. Naka,et al. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. , 1999, Trends in biochemical sciences.
[39] D. Hilton,et al. Negative regulation of the JAK/STAT pathway , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.
[40] D. Hanahan,et al. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. , 1999, Cancer research.
[41] S. Rane,et al. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled , 2000, Oncogene.
[42] J. Grandis,et al. STAT signaling in head and neck cancer , 2000, Oncogene.
[43] S. Sukumar,et al. Compromised HOXA5 function can limit p53 expression in human breast tumours , 2000, Nature.
[44] N. Danial,et al. JAK-STAT signaling activated by Abl oncogenes , 2000, Oncogene.
[45] J. Darnell,et al. The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.
[46] T. Yeatman,et al. Role of Src expression and activation in human cancer , 2000, Oncogene.
[47] K. Shuai,et al. Modulation of STAT signaling by STAT-interacting proteins , 2000, Oncogene.
[48] M. Loh,et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.
[49] D. Tweardy,et al. Interleukin‐6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway , 2000, The Prostate.
[50] Simon C Watkins,et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[51] G. Semenza,et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.
[52] R. Kerbel,et al. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. , 2000, The journal of investigative dermatology. Symposium proceedings.
[53] J. Gibbs. Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.
[54] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[55] S. Akira. Roles of STAT3 defined by tissue-specific gene targeting , 2000, Oncogene.
[56] Roy Garcia,et al. STATs in oncogenesis , 2000, Oncogene.
[57] Mikhail Chernov,et al. Regulation of c‐myc expression by IFN‐γ through Stat1‐dependent and ‐independent pathways , 2000 .
[58] E. Andreu,et al. Blockade of the Bcr-Abl Kinase Activity Induces Apoptosis of Chronic Myelogenous Leukemia Cells by Suppressing Signal Transducer and Activator of Transcription 5–Dependent Expression of Bcl-XL , 2000, The Journal of experimental medicine.
[59] J. Turkson,et al. STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.
[60] J. Griffin,et al. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. , 2000, Blood.
[61] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[62] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[63] T. Hirano,et al. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.
[64] Thomas S. Lin,et al. STAT signaling in the pathogenesis and treatment of leukemias , 2000, Oncogene.
[65] J. Turkson,et al. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling , 2000, Oncogene.
[66] J. Griffin,et al. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. , 2000, Blood.
[67] T. Veikkola,et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.
[68] J. Darnell,et al. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[69] J. Turkson,et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.
[70] J. Ihle. The Stat family in cytokine signaling. , 2001, Current opinion in cell biology.
[71] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[72] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[73] T. Yeatman,et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[74] B. Elliott,et al. Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells* , 2001, The Journal of Biological Chemistry.
[75] J. Turkson,et al. Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.
[76] R. Jove,et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.
[77] B. Nelson,et al. Stat5 and Sp1 Regulate Transcription of the Cyclin D2 Gene in Response to IL-21 , 2001, The Journal of Immunology.
[78] J. Herman,et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity , 2001, Nature Genetics.
[79] Hua Yu,et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells , 2001, Oncogene.
[80] Hua Yu,et al. Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells , 2002, Oncogene.
[81] J. Pow-Sang,et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.
[82] J. Darnell,et al. Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.
[83] L. Ellis,et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.
[84] M. Baccarani,et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. , 2002, Blood.
[85] John K. Buolamwini,et al. Novel Molecular Targets for Cancer Drug Discovery , 2002 .
[86] N. Bazan,et al. Phosphorylation of STAT-3 in Response to Basic Fibroblast Growth Factor Occurs through a Mechanism Involving Platelet-activating Factor, JAK-2, and Src in Human Umbilical Vein Endothelial Cells , 2002, The Journal of Biological Chemistry.
[87] Drew M. Pardoll,et al. Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.
[88] R. Jove,et al. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[89] R. Jove,et al. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis , 2002, Oncogene.
[90] J. Darnell. Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.
[91] D. Frank,et al. The role of STATs in apoptosis. , 2002, Current molecular medicine.
[92] R. DePinho,et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.
[93] C. Meijer,et al. Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation , 2002, The Journal of Immunology.
[94] D. Levy,et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death , 2002, Oncogene.
[95] B. Smith,et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.
[96] J. Grandis,et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[97] D. Boger,et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[98] G. Semenza. Involvement of hypoxia-inducible factor 1 in human cancer. , 2002, Internal medicine.
[99] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.
[100] William C Hahn,et al. Rules for making human tumor cells. , 2002, The New England journal of medicine.
[101] Qian Zhang,et al. Multilevel Dysregulation of STAT3 Activation in Anaplastic Lymphoma Kinase-Positive T/Null-Cell Lymphoma1 , 2002, The Journal of Immunology.
[102] Hua Yu,et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth , 2002, Oncogene.
[103] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[104] M. Masuda,et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. , 2002, Cancer research.
[105] J. Pow-Sang,et al. Constitutive Activation of Stat 3 in Human Prostate Tumors and Cell Lines : Direct Inhibition of Stat 3 Signaling Induces Apoptosis of Prostate Cancer Cells 1 , 2002 .
[106] Chia-Hung Chou,et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway , 2003, Oncogene.
[107] J. S. Gutkind,et al. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. , 2003, Cancer research.
[108] K. Sayama,et al. Nuclear Translocation of Phosphorylated STAT3 Is Essential for Vascular Endothelial Growth Factor-induced Human Dermal Microvascular Endothelial Cell Migration and Tube Formation* , 2003, Journal of Biological Chemistry.
[109] M. Bartoli,et al. The FASEB Journal express article 10.1096/fj.02-1084fje. Published online June 17, 2003. VEGF differentially activates STAT3 in microvascular endothelial cells , 2022 .
[110] G. Feldman,et al. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. , 2003, Blood.
[111] J. Abbruzzese,et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.
[112] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[113] A. Yang,et al. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. , 2003, Cancer research.
[114] J. Herman,et al. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. , 2003, Blood.
[115] J. Turkson,et al. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells , 2003, Oncogene.
[116] J. Grandis,et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[117] E. Fikrig,et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[118] D. Frank. StAT signaling in cancer: insights into pathogenesis and treatment strategies. , 2003, Cancer treatment and research.
[119] Shu-Wha Lin,et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia , 2003, Genes, chromosomes & cancer.
[120] B. Cochran,et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells , 2003, BMC Cancer.
[121] J. Turkson,et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. , 2003, Cancer research.
[122] Hua Yu,et al. A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.
[123] P. Heinrich,et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.
[124] D. Pardoll,et al. Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.
[125] J. Grandis,et al. Src Kinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of the Head and Neck* , 2003, Journal of Biological Chemistry.
[126] R. Jove,et al. Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.
[127] J. Turkson,et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. , 2004, Molecular cancer therapeutics.
[128] Hua Yu,et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.
[129] J. Darnell,et al. Transcriptionally active Statl is required for the antiproliferative effects of both interferon a and interferon , 2005 .